It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Optimizing Recombinant Cereblon-Midi Expression in E. coli Through Smart Strain Choice
In this article we discuss our workflow for selecting the optimum E. coli strain for producing a target protein and present example data on how this was key to the production of high quality Cereblon-Midi protein to support X-ray crystallography.
Choosing the right E. coli strain?
Selecting the right E. coli strain is one of the most important decisions when planning recombinant protein expression. Even subtle differences between host strains – such as expression control, protease activity, chaperone availability, or plasmid compatibility – can dramatically influence both protein yield and quality. The choice of strain can determine whether your expression run results in a clean, high-yield preparation or a challenging, low-quality product.
Within the Protein & Structure department at Sygnature Discovery, our microbial expression team utilizes a broad portfolio of E. coli strains and apply their scientific expertise to match constructs with the most suitable host. By understanding the specific requirements of your protein, such as solubility, toxicity, folding complexity, or need for disulfide bond formation, we can design an expression strategy that maximizes the chance of success and drives a project efficiently toward being able to generate high-quality recombinant protein.
Why the right E. coli strain matters?
Even the best designed protein expression constructs can behave unpredictably once they reach the bench. Even a well designed expression strategy can quickly run into problems such as:
Leaky expression leading to premature toxicity
Proteins that stress or kill the host
Low transformation efficiency
Misfolding or aggregation
Poor or inconsistent yields
These challenges often stem from choosing a host strain that isn’t well matched to the protein’s characteristics. That’s why our microbial expression team takes a tailored, data-driven approach. We can review known behavior or sequence features of your construct, and the specific goals of your project and from there select the strain most likely to give robust expression. When needed, we run small-scale comparison screens to identify the “best performer” experimentally. This ensures the expression strategy is built on the strongest foundation possible and maximizes the chances of downstream success.
Troubleshooting through smart strain selection
Many recombinant proteins need more than a “standard” E. coli host strain. Some require tighter promoter control, enhanced folding assistance, improved transformation efficiency, or specialist capabilities such as in vivo biotinylation. To support these diverse needs, our microbial expression team maintains a broad toolbox of E. coli strains and strain–plasmid combinations in the laboratory. With this range, we can troubleshoot issues such as poor transformability, expression toxicity, rare codon usage, plasmid instability, or low yields – choosing strains that give your protein construct the best possible environment to succeed.
Behind the Strains: what makes them different?
Each E. coli strain brings unique features that can dramatically influence expression outcomes. Here are a few examples from our current toolkit:
DE3 Lysogen (DE3) Contains a chromosomal T7 RNA polymerase gene under the lacUV5 promoter, making it the go-to choice for T7 driven expression systems.
pLysS Expresses T7 lysozyme, which suppresses background transcription and reduces leaky expression—particularly valuable for toxic or tightly regulated proteins.
One Shot™ Format Convenient, single use transformation tubes that minimize contamination risks and streamline workflows.
BL21 vs. BL21 Gold BL21 Gold’s Hte phenotype boosts transformation efficiency (>1×10⁸ cfu/µg), and its endA inactivation reduces plasmid degradation, making it ideal for difficult constructs or low abundance DNA preps.
BirA2 Enables in vivo biotinylation when biotin is added during induction, offering a powerful advantage for affinity purification, assay development or downstream binding studies.
Cloning Strains For subcloning workflows, we predominantly use DH5α, which consistently delivers strong transformation efficiency and robust plasmid yields across our prep methods.
Our available E. coli cell strains
BL21 Gold (DE3)
BL21 Gold (DE3) / pCDF‑BirA2
BL21 Gold (DE3) pLysS
One Shot™ BL21 Star™ (DE3)
One Shot™ BL21 Star™ (DE3) pLysS
BL21 Gold (DE3) RIL
DH5α
MAX Efficiency DH10Bac
C41
C41 + pLysS
C43
C43 + pLysS
Shuffle T7 Express
Rosetta 2 (DE3) pLysS
Rosetta 2 / pCDF‑BirA2
How do we choose the right strain type?
While clients often come to us with a preferred strain type in mind, we can use a structured troubleshooting workflow (see Figure 1) to evaluate each construct’s requirements and predict which host is most likely to deliver strong, reliable protein yields. This approach helps us match the biology of your protein with the strengths of specific cell strains, ensuring the expression system is set up for success from the very start.
Figure 1:E. coli troubleshooting workflow
We work closely with our clients to identify the expression strategy and cell system that best fits their specific project needs. Whether you’re dealing with challenging constructs, have specialized expression requirements, or complex downstream applications, our expert team is here to guide you toward the most effective and reliable path forward.
Example Case Study: Improving the Expression Yield of Cereblon-Midi
We have recently expressed, purified and crystallized Cereblon-Midi, a key protein in the targeted protein degradation system (for more information see our case study ).
To establish the most optimal conditions for expression of this protein we carried out a panel of small-scale expressions and purifications to compare 5 different E. coli strains. Following the expression grows there were significant differences observed in the harvested pellet size between the cell strains as shown in Figure 2.
Figure 2: Harvested cell mass comparison Harvested wet cell mass from each flask showed >3 fold difference between grow rates of the different E. coli strains.
A comparable portion of each of the cell pellets was lysed and purified by Nickel IMAC to maintain the ratio differences in cell paste yield. Figure 3 shows the SDS PAGE and protein yields from each cell strain.
Figure 3: Different soluble protein yields across the cell strains. Reduced SDS-PAGE images and post IMAC yield of purified proteins from each cell strain shows a marked difference in soluble expression levels in these small-scale grows.
It is clear from the contrast between Figures 2 and 3 that the paste yield is not indicative of the final protein quantities obtained. In this example E. coli cell strain 3 was found to be the “best expressor” of soluble Cereblon-Midi and was taken forwards as the most efficient system for us to produce quality soluble protein at the scale required for crystallography.